Put MOTS-c and SS-31 side by side and you would be forgiven for expecting two variations on a theme. Both are peptides. Both act on mitochondria. Both come up constantly in conversations about aging and metabolism. And yet they are close to opposites — in where they come from, in how they work, and in how far along the evidence for each has traveled. That contrast is not a technicality. It is the single clearest illustration of why “mitochondrial medicine” is not one strategy but several, and why the difference matters when you read a claim about either.
Different origins
MOTS-c is endogenous — the body makes it. It is a 16-amino-acid peptide encoded within the mitochondrial genome itself, a genuine internal signal that rises with exercise and appears to decline with age. Because it is based on an endogenous signal, external administration works with biology the body already uses — though giving a peptide from outside will not necessarily reproduce the natural timing, concentration, or distribution of the internal signal.
SS-31 (elamipretide) is synthetic — a small tetrapeptide designed in the lab to do a specific physical job. It is not a signal the body sends; it is an engineered tool designed to preferentially localize to the inner mitochondrial membrane. One is a message evolution wrote; the other is a device chemists built. That difference sets up everything that follows.
Different mechanisms
This is the heart of the contrast. MOTS-c works by signaling. It converges on AMPK — the cell’s low-energy sensor — and shifts the cell into fuel-burning, stress-adapting programs, echoing some of the metabolic effects of exercise. Its influence is regulatory: it changes what the cell does, nudging a network of responses.
SS-31 is proposed to work by structure. It binds cardiolipin, the lipid that holds the inner mitochondrial membrane’s folds and energy complexes in their efficient arrangement, and is thought to help that architecture stay intact under stress. On this model — supported primarily by mechanistic and preclinical work — it does not tell the cell to adapt so much as keep the physical machinery from falling apart.
A useful analogy: MOTS-c is like a coach calling better plays, while SS-31 is like reinforcing the stadium the game is played in. Both can matter to the outcome, but they operate on entirely different levels — one informational, one physical — and there is no reason to expect them to help the same problems in the same way.
Different evidence stages
Here the two diverge most sharply, and reading them accurately means keeping the stages distinct.
SS-31 has reached the clinic. In 2025 it earned FDA accelerated approval for Barth syndrome — a rare disease of cardiolipin — making it the first mitochondria-targeted therapeutic ever approved. That is a real human milestone. It comes with two honest asterisks: the approval is accelerated (granted on an intermediate strength endpoint, pending confirmatory trials), and a larger trial in the broader condition of primary mitochondrial myopathy, MMPOWER-3, did not meet its primary endpoints. SS-31 is approved for one specific, mechanism-matched disease, and unproven for the wider aging uses it is often associated with.
MOTS-c remains earlier. Its most striking results — improved insulin sensitivity, protection against diet-induced weight gain, restored physical performance in aged animals — come from mouse studies, alongside strong evidence that MOTS-c is a real human physiological signal. What does not yet exist is a large human trial showing that supplementing it reproduces those benefits. The mechanism and animal data are exciting; the human interventional evidence is still to come.
So one peptide has crossed into approved therapy for a narrow indication, and the other sits at the compelling-but-preclinical frontier. Neither status is a verdict on the other. They are simply at different points on the same long road from idea to proof.
What the comparison teaches
The temptation is to ask which one is “better.” That question mostly dissolves on contact with the biology, because they are trying to do different things. A membrane stabilizer and a metabolic signal are not competitors so much as two instruments aimed at different failure modes of the same organelle — structural decay in one case, lost signaling and adaptation in the other. A mature mitochondrial medicine may ultimately combine approaches at both levels, plus others.
That is the real lesson of setting them together: mitochondrial aging is multi-layered, and so the response will be too. Recognizing that a molecule works by signaling versus by structure — and knowing whether its evidence sits in a mouse or in an FDA label — is exactly the literacy that turns a crowded field of claims into a clear map of a genuinely thrilling area of science.
Why it matters
MOTS-c and SS-31 are a natural teaching pair: same organelle, opposite strategies, different stages of proof. Holding both in view at once guards against the two most common errors in reading this space — flattening every mitochondrial peptide into the same story, and mistaking an early animal signal for a clinical result, or vice versa. Seen clearly, they do not compete for the title of best mitochondrial peptide. Together they sketch the shape of what mitochondrial medicine is becoming, and that bigger picture is more exciting than any single molecule.